IMPROVING APPROPRIATE USE OF INTRAVENOUS IMMUNOGLOBULIN IN NEUROLOGICAL DISORDERS AT HOSPITAL KUALA LUMPUR

Authors

  • Tan Ai Leen Author
  • Ziran Nadiah Ghazali Author
  • Dhayalen Krishnan Author
  • Yeak Chee Yan Author
  • Hazrin Mohamed Radzi Author
  • Wan Noor Hazimah Wan Harun Author
  • Mohd Izwan Che Nuddin Author
  • Farizan Abdul Ghaffar Author
  • Shanthi Viswanathan Author

DOI:

https://doi.org/10.63719/qbulletin.v1i35.280

Keywords:

Intravenous immunoglobulin (IVIG), neurological disorders, appropriate use, drug utilisation, quality improvement study

Abstract

Intravenous Immunoglobulin (IVIG) therapy is used in various immune-mediated, inflammatory and immunodeficiency disorders. The appropriate use of IVIG can be defined as its correct indication, dose, frequency, duration and administration. A verification study conducted between October and December 2021 revealed that 61.2% of IVIG usage in neurological disorders was inappropriate, potentially exposing patients to unfavourable clinical outcomes and risk of adverse events. This study aimed to increase the percentage of appropriate IVIG use in neurological disorders, setting a standard of 95%. A quality improvement study was conducted from 2021 to 2024, involving all IVIG cases initiated at neurology wards and clinics. Patients receiving IVIG treatment were assessed for its appropriateness. Findings from the survey among healthcare workers showed that the contributing factors to inappropriate IVIG use were easy IVIG accessibility, uncertainty of indications, unsure proper administration and dose, prolonged treatment duration and the absence of standardised local guidelines. In Cycle 1, indications were streamlined by prioritising peripheral nervous system disorders and limiting treatment initiation to consultants. The IVIG infusion guide was developed to educate nurses. During Cycle 2, an IVIG indication priority table was established by classifying neurological disorders into four classes of priority based on clinical evidence. An electronic spreadsheet-based IVIG dose calculator and administration chart facilitated accurate dosage calculations and appropriate monitoring. Lastly, in Cycle 3, an IVIG guideline for neurological disorders was developed, intended as a standard guide in Hospital Kuala Lumpur. The proportion of appropriate IVIG use increased from 38.8% at baseline to 52.3% in Cycle 1, 87.0% in Cycle 2 and 96.5% in Cycle 3. Conversely, Achievable Benefit Not Achieved decreased from 56.2% to 42.7% in Cycle 1, and was further reduced to 8.0% in Cycle 2 and -1.5% in Cycle 3. Additionally, proper monitoring allows early detection of infusion-related reactions. The IVIG guideline will be further promoted to other departments within HKL and to neurology centres throughout Malaysia.

Author Biographies

  • Tan Ai Leen

    Department of Pharmacy, Hospital Kuala Lumpur, Ministry of Health Malaysia

  • Ziran Nadiah Ghazali

    Department of Pharmacy, Hospital Kuala Lumpur, Ministry of Health Malaysia

  • Dhayalen Krishnan

    Department of Neurology, Hospital Kuala Lumpur, Ministry of Health Malaysia

  • Yeak Chee Yan

    Department of Pharmacy, Hospital Kuala Lumpur, Ministry of Health Malaysia

  • Hazrin Mohamed Radzi

    Department of Pharmacy, Hospital Kuala Lumpur, Ministry of Health Malaysia

  • Wan Noor Hazimah Wan Harun

    Department of Pharmacy, Hospital Kuala Lumpur, Ministry of Health Malaysia

  • Mohd Izwan Che Nuddin

    Department of Neurology, Hospital Kuala Lumpur, Ministry of Health Malaysia

  • Farizan Abdul Ghaffar

    Department of Pharmacy, Hospital Kuala Lumpur, Ministry of Health Malaysia

  • Shanthi Viswanathan

    Department of Neurology, Hospital Kuala Lumpur, Ministry of Health Malaysia

References

1. Garis Panduan Formulari Ubat Kementerian Kesihatan Malaysia [Internet]. Program Perkhidmatan Farmasi. 2025. Available from: https://pharmacy.moh.gov.my/ms/dokumen/garis-panduan-formulari-ubat-kementerian-kesihatan-malaysia.html

2. Dalakas MC. Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy. Neurotherapeutics. 2021 Oct 1;18(4):2397–418. doi:10.1007/s13311-021-01108-4 PubMed PMID: 34766257.

3. Foster R, Suri A, Filate W, Hallett D, Meyer J, Ruijs T, et al. Use of intravenous immune globulin in the ICU: a retrospective review of prescribing practices and patient outcomes. Transfusion Medicine. 2010 Jul 21;20(6):403–8.

4. Fakhari Z, Farsaei S, Sabzghabaee AM. Predicting Factors for the Pattern of Intravenous Immunoglobulin Utilization in a Middle Eastern University Hospital. J Res Pharm Pract. 2018 Oct;7(4):188–94. doi:10.4103/jrpp.jrpp_18_73

5. Lee JL, Mohd Saffian S, Makmor-Bakry M, Islahudin F, Alias H, Ali A, et al. Prescribing Practices of Intravenous Immunoglobulin in Tertiary Care Hospitals in Malaysia: A Need for a National Guideline for Immunoglobulin Use. Front Pharmacol. 2022 Jun 9;13. doi:10.3389/fphar.2022.879287

6. Hsu LI, Chen JW, Lin DT, Hung YS, Hou SM. Clinical use of intravenous immunoglobulin in Taiwan: A 10-year population study. Journal of the Formosan Medical Association. 2021 Oct 1;120(10):1921–5. doi:10.1016/j.jfma.2021.02.017 PubMed PMID: 33726936.

7. Palabrica FRR, Kwong SL, Padua FR. Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study. Asia Pac Allergy. 2013 Oct;3(4):249–56. doi:10.5415/apallergy.2013.3.4.249

8. Perez EE, Orange JS, Bonilla F, Chinen J, Chinn IK, Dorsey M, et al. Update on the use of immunoglobulin in human disease: A review of evidence. Journal of Allergy and Clinical Immunology. 2017 Mar 1;139(3):S1–46. doi:10.1016/j.jaci.2016.09.023 PubMed PMID: 28041678.

9. Boulis A, Goold S, Ubel PA. Responding to the Immunoglobulin Shortage: A Case Study. Journal of Health Politics Policy and Law. 2002 Dec 1;27(6):977 1000.10. Hartmann J, Klein HG. Supply and demand for plasma-derived medicinal products - A critical reassessment amid the COVID-19 pandemic. Transfusion. Blackwell Publishing Inc.; 2020. p. 2748–52. doi:10.1111/trf.16078 PubMed PMID: 32856742.

11. Herth FJF, Sakoulas G, Haddad F. Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case Series. 2021 Jan 1;99(12):1145–53. doi:10.1159/000511376 PubMed PMID: 33316806.

12. Nguyen AA, Habiballah SB, Platt CD, Geha RS, Chou JS, McDonald DR. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution! Clinical Immunology. Academic Press Inc.; 2020. doi:10.1016/j.clim.2020.108459 PubMed PMID: 32418917.

13. Ziyun S, Yongwen F, Li Z, Qifeng X, Ming L, Zheying L, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clinical & Translational Immunology. 2020 Jan;9(10).

14. González-Guerrero Celia, Montoro-Ronsano José Bruno. Evaluation of the Immunoglobulin Use in Inflammatory Systemic and Immuno-Mediated Illnesses in a Tertiary Hospital. Journal of Pharmacy and Pharmacology. 2015 Apr 28;3(4). doi:10.17265/2328-2150/2015.04.006

15. Solís-Díez G, Turu-Pedrola M, Roig-Izquierdo M, Zara C, Vallano A, Pontes C. Dealing With Immunoglobulin Shortages: A Rationalization Plan From Evidence-Based and Data Collection. Front Public Health. 2022 May 19;10. doi:10.3389/fpubh.2022.893770 PubMed PMID: 35664094.

16. Zahari NH, Abd Hamid IJ, Tuan Din SA, Hashim IF, Zainudeen ZT, Shariff NM, et al. Practise of Immunoglobulin Replacement Therapy in Primary and Secondary Immunodeficiencies: A Single Centre Experience from Malaysia. Malaysian Journal of Medical Sciences. 2023;30(3):112–21. doi:10.21315/mjms2023.30.3.10

17. Ruiz-Antorán B, Escasany AA, Ferraz AV, Danés Carreras I, Riba N, Escudero SM, et al. Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol. Eur J Clin Pharmacol. 2010;(6):633–41. doi:10.1007/s00228-010-0800-y

18. Dawoud T, Tatari H, Gebran N. A utilisation review of intravenous immunoglobulin in a tertiary care hospital in united arab emirates. European Journal of Hospital Pharmacy. 2012;19(3):286–8. doi:10.1136/ejhpharm-2012-000070

19. Choo SJ, Ng CZ, Ong YJ, Kamarul Baharin KS, Chang CT. Intravenous human immunoglobulin utilization patterns and cost analysis in a Malaysian tertiary referral hospital. J Pharm Policy Pract. 2022 Dec 1;15(1). doi:10.1186/s40545-022-00430-2

20. Mehta K. Intravenous Immunoglobulin (IVIg) prescribing guidance [Internet]. 2017. Report. Available from: http://www.igd.nhs.uk/clinical-info/

21. Elovaara I, Apostolski S, Van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. European Journal of Neurology. 2008. p. 893–908. doi:10.1111/j.1468-1331.2008.02246.x PubMed PMID: 18796075.

22. Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International Consensus Guidance for Management of Myasthenia Gravis 2020 Update. Neurology. Lippincott Williams and Wilkins; 2021. p. 114–22. doi:10.1212/WNL.0000000000011124 PubMed PMID: 33144515.

23. Clinical guidelines for immunoglobulin use -second edition update Scotland 1 [Internet]. [cited 2026 Feb 23]. Available from: https://www.nppeag.scot.nhs.uk/wp-content/uploads/Scottish-guidelines-v2.pdf

24. Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, et al. Autoimmune encephalitis: Proposed best practice recommendations for diagnosis and acute management. Journal of Neurology, Neurosurgery and Psychiatry. BMJ Publishing Group; 2021. p. 757–68. doi:10.1136/jnnp-2020 325300 PubMed PMID: 33649022.

25. Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. Eur J Neurol. 2021 Nov 1;28(11):3556–83. doi:10.1111/ene.14959 PubMed PMID: 34327760.

26. Tan AL, Krishnan D, Ghazali ZN, Yeak CY, Mohamed Radzi H, Wan Harun WNH, et al. Guideline on Prescribing, Supplying and Administration of Immunoglobulin (IVIG) in Neurological Disorders, Hospital Kuala Lumpur (GPS-Ig). 2024. Report.

27. Criteria for the clinical use of intravenous immunoglobulin in Australia Second Edition Standing Council on Health [Internet]. 2012. Available from: https://www.rch.org.au/uploadedFiles/Main/Content/bloodtrans/Criteria_for_the_Clinical_Use_of_IVIg_in_Australia.pdf

28. Criteria for the clinical use of intravenous immunoglobulin in Australia Second Edition Standing Council on Health [Internet]. 2012. Available from: https://www.rch.org.au/uploadedFiles/Main/Content/bloodtrans/Criteria_for_the_Clinical_Use _of_IVIg_in_Australia.pdf

29. Privigen® [Internet]. [cited 2024 August 24]. https://labeling.cslbehring.com/DS/AU/Privigen/EN/Privigen-NZ-Data-Sheet.pdf

Downloads

Published

31-10-2026

Issue

Section

Articles

How to Cite

1.
IMPROVING APPROPRIATE USE OF INTRAVENOUS IMMUNOGLOBULIN IN NEUROLOGICAL DISORDERS AT HOSPITAL KUALA LUMPUR. Q Bulletin [Internet]. 2026 Oct. 31 [cited 2026 Nov. 23];1(35). Available from: https://journal.nih.gov.my/index.php/qbulletin/article/view/280

Similar Articles

31-40 of 40

You may also start an advanced similarity search for this article.